Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [¹⁷⁷Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.

ABSTRACT:

Background

In many solid tumors, early tumor shrinkage predicts the durability of treatment response. It is unclear whether this is the case for neuroendocrine tumors treated with peptide receptor radionuclide therapy (PRRT).

Methods

Data from the phase III NETTER-1 study of [¹⁷⁷Lu]Lu-DOTA-TATE (¹⁷⁷Lu-DOTATATE) for the treatment of advanced, well-differentiated, midgut NETs were used to investigate whether objective tumor shrinkage (local review) with ¹⁷⁷Lu-DOTATATE is associated with progression-free survival (PFS) and overall survival (OS) duration.

Results

Overall, 117 patients were treated with ¹⁷⁷Lu-DOTATATE (four cycles of 7.4 GBq every 8 weeks). In a landmark analysis, best tumor shrinkage from baseline until data cut

SUBMITTER: Pavel M 

PROVIDER: S-EPMC12020026 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature